HIV Returns in Patients Thought Cured

The virus is back in two patients in Boston who received bone-marrow transplants and did not have detectable levels of virus for months.

Written byAbby Olena, PhD
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

HIV retrovirusWIKIMEDIA, PHD DRE

Physician-scientists reported in July that two male patients had stopped anti-retroviral therapy and were HIV-free after bone-marrow transplants that occurred in 2008 in one man and 2010 in the second. Now, the scientists have announced that HIV is back in both patients.

“It’s disappointing and very sobering,” virologist Deborah Persaud of the Johns Hopkins Children’s Center in Baltimore, Maryland, told Nature News.

The men were given high-risk bone-marrow transplants to treat blood cancer and had no detectable levels of HIV in their blood eight months post-transplant. They each stopped taking anti-retroviral drugs earlier this year and did not test positive for HIV for months. Timothy Henrich of Brigham and Women’s Hospital in Boston, one of the patients’ physicians, said today in a statement that one ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • abby olena

    As a freelancer for The Scientist, Abby reports on new developments in life science for the website. She has a PhD from Vanderbilt University and got her start in science journalism as the Chicago Tribune’s AAAS Mass Media Fellow in 2013. Following a stint as an intern for The Scientist, Abby was a postdoc in science communication at Duke University, where she developed and taught courses to help scientists share their research. In addition to her work as a science journalist, she leads science writing and communication workshops and co-produces a conversational podcast. She is based in Alabama.  

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies